Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune thrombocytopenias.

R H Aster

    Hospital Practice (Office Ed.)
    |November 1, 1983
    PubMed
    Summary

    Antibody-mediated platelet destruction causes bleeding disorders with varied severity. Diverse antibody origins necessitate tailored treatments like steroids or apheresis for immune thrombocytopenia.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Intravenous immunoglobulin as an adjunct therapy in persisting heparin-induced thrombocytopenia.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2018
    Same author

    Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis.

    Journal of thrombosis and haemostasis : JTH·2012
    Same author

    Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.

    Journal of thrombosis and haemostasis : JTH·2009
    Same author

    HPA-1a/b(PlA1/A2,Zwa/b): the odyssey of an alloantigen system.

    Immunohematology·2007
    Same author

    Heparin-induced immune thrombocytopenia - a clinical or laboratory diagnosis?

    Journal of thrombosis and haemostasis : JTH·2006
    Same author

    Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.

    Journal of thrombosis and haemostasis : JTH·2006

    Area of Science:

    • Immunology
    • Hematology
    • Pediatrics

    Background:

    • Platelet destruction mediated by antibodies is a common feature in several bleeding disorders.
    • Clinical presentations range from mild to life-threatening, influenced by antibody origins.

    Purpose of the Study:

    • To elucidate the common pathogenic mechanism and diverse etiologies of antibody-mediated thrombocytopenic bleeding disorders.
    • To outline treatment strategies for these conditions.

    Main Methods:

    • Review of clinical manifestations and antibody origins (transplacental, exogenous, autogenous).
    • Summary of therapeutic interventions including corticosteroids, exchange transfusion, apheresis, and splenectomy.

    Main Results:

    • Antibody-induced platelet destruction is the unifying factor across these disorders.
    • Diverse antibody sources lead to varied clinical outcomes and treatment responses.

    Conclusions:

    • Understanding the origin of antibodies is crucial for managing immune thrombocytopenia.
    • Treatment selection depends on disease severity and antibody type, with options ranging from medical to surgical interventions.

    Related Experiment Videos